Hiromichi Kimura, founder and Managing Partner of Fast Track Initiative. See sector focus and contact routes.
Hiromichi Kimura, founder and Managing Partner of Fast Track Initiative, invests exclusively in early-stage life sciences and healthcare ventures in Japan, often entering at or before company formation with a focus on biotech, medtech, and healthtech. His distinctive thesis blends venture investing with venture building, actively supporting researchers in patenting, business planning, and initial capital raising due to his own background in commercializing academic research. Notable portfolio companies include Cytlimic (which raised ¥1.3B in 2019), Braizon Therapeutics, Modulus Discovery, and CellSeed (the firm’s only exit). While specific check sizes are not publicly disclosed, the firm typically targets deals in the $5–10 million range and has made 23+ investments since 2004.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Hongo when building a target list.
Investors like Hiromichi Kimura · Full investor directory · Investor access · Company funding database